Granules India acquires Senn Chemicals AG to expand peptide therapeutics and CDMO capabilities
Acquisition strengthens Granules’ entry into the peptide-based therapeutics market and enhances CDMO capabilities through Senn’s…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Granules India
Budget expectations: Leaders opine for incentives in the nutra and API manufacturing sectors
Industry players urge the government to prioritise funding for research into botanical herbs and address the challenge of API…
Granules Pharmaceuticals gains U.S. FDA approval for Lisdexamfetamine Dimesylate chewable tablets
New approval supports treatment for ADHD and binge eating disorder while addressing critical drug shortages
Granules India updates on US FDA inspection at Gagillapur Facility
OAI classification prompts proactive remediation plan; no impact on current manufacturing or product distribution
Granules India’s Gagillapur facility classified as “Official Action Indicated” following US FDA…
Company responds to observations and initiates improvements in collaboration with external experts
Granules’ net zero commitment approved by SBTi
Granules' climate targets span near-term, long-term, and net-zero goals, aligned with the 1.5°C Pathway
Granules India appoints Ovais Sarmad as sustainability advisor
Ovais Sarmad to guide Granules India on climate policy and environmental initiatives
Granules India presented with the Golden Peacock Award for sustainability
Granules India aims to achieve net zero emissions by 2050, in alignment with the Science Based Targets initiative (SBTi)
Granules India receives ANDA approval for Glycopyrrolate Oral Solution
It is bioequivalent and therapeutically equivalent to the reference listed drug, Cuvposa Oral Solution, 1 mg/5 mL of Merz…
Granules India gains ANDA approval for Trazodone tablets
The current annual US market for Trazodone tablets is approximately $128 million, according to MAT Jun 2024, IQVIA/IMS Health